Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
Cellectis, a clinical-stage biotechnology company listed on Euronext Growth (ALCLS) and Nasdaq (CLLS), held its shareholders' general meeting on June 28, 2024, in Paris. Approximately 40% of shares were exercised during the meeting, resulting in the adoption of resolutions 1 through 28 and the rejection of resolution 29, aligning with management's recommendations. Detailed voting results and resolutions are accessible on Cellectis' official website.
- Adoption of resolutions 1 through 28, reflecting strong shareholder alignment with management's recommendations.
- Only 40% of shares were exercised, indicating potentially low shareholder engagement.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
At the meeting, during which approximately
The detailed results of the vote and the resolutions are available on Cellectis’ website: https://www.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 24 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
For further information on Cellectis, please contact:
Media contact:
Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contacts:
Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577
Attachment
![](https://ml.globenewswire.com/media/MWJiMTQ1Y2ItZjczZC00MGUxLWE4NDYtNDdiYzAzMjUyMWVjLTEwNjE0NDg=/tiny/Cellectis-Inc-.png)
FAQ
What were the outcomes of Cellectis' shareholders' meeting held on June 28, 2024?
How many shares were exercised at Cellectis' shareholders' meeting in 2024?
Where can I find the detailed voting results of Cellectis' 2024 shareholders' meeting?
What is the stock symbol for Cellectis?